EMA Reflection Paper on AI in the Drug Lifecycle: What Clinical Research Teams Need to Operationalize
In September 2024, the European Medicines Agency adopted its Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle (EMA/CHMP/CVMP/83833/2023). Both the Committee for Medicinal Products for Human Use (CHMP) and the Committee for Veterinary Medicinal Products (CVMP) signed off. The paper received over 1,300 consultation responses — a signal of how seriously industry is taking this.
This is the EMA's definitive statement on how AI should be used across the entire drug development pipeline. Unlike the FDA's more flexible, dialogue-driven approach, the EMA lays out a structured, risk-tiered framework that maps specific expectations to each stage of the lifecycle. If your clinical trial program touches the EU market, this paper defines what regulators will expect when AI is part of your evidence package.
We read the full document. Here's the operational playbook.
The core framework: two risk dimensions
The EMA introduces two risk categories that determine how much scrutiny your AI application will receive. These are distinct from the EU AI Act's risk classification — they're specific to the medicinal product context.
High patient risk applies to AI systems whose outputs directly affect patient safety. Examples include AI-driven dose selection, patient stratification that determines treatment assignment, and safety signal detection that influences benefit-risk assessments.
High regulatory impact applies to AI systems whose outputs carry substantial weight in regulatory decision-making. This includes AI used to generate pivotal efficacy data, support primary endpoint analysis, or produce evidence that directly informs marketing authorization decisions.
When your AI application falls into either category, the EMA expects you to engage early through scientific advice or qualification of innovative development methods. Waiting until the marketing authorization application to explain your AI methodology is the wrong strategy.
Compliance callout
The EMA explicitly names four responsible parties: marketing authorization applicants, marketing authorization holders, clinical trial sponsors, and manufacturers. If you're a CRO running a trial on behalf of a sponsor, the sponsor bears responsibility for ensuring AI compliance — but you need to build the documentation trail that makes that possible.
Lifecycle stage requirements
The reflection paper walks through each stage of the medicinal product lifecycle. Here's what matters at each level.
Drug discovery
The EMA takes a light touch here. If AI is used during drug discovery and the results feed into a regulatory submission, the principles for non-clinical development apply. But the regulatory risk is acknowledged as low — poor AI performance at this stage mainly affects the sponsor, not patients. You don't need to over-document your target identification algorithms unless they directly inform first-in-human study design.
Non-clinical development
This is where requirements tighten. Any AI application that affects patient safety — such as efficacy and safety modeling that informs first-in-human studies — or has high regulatory impact must follow OECD Good Laboratory Practice (GLP) guidance. The EMA specifically calls out the OECD advisory documents on applying GLP principles to computerized systems and data integrity.
Operationally, this means your SOPs must be updated to explicitly cover AI/ML use. If you're using AI for toxicology prediction, ADMET modeling, or dose-response analysis that feeds into IND-equivalent submissions, the model development logs, training data provenance, and validation records become part of your GLP-compliant documentation.
Clinical trials
AI/ML systems used in clinical trials must meet ICH GCP requirements. The EMA is unambiguous on this point. If the AI system has high regulatory impact or high patient risk, and the method hasn't been previously qualified by the EMA, expect comprehensive assessment during authorization procedures and inspection.
Specifically, the EMA states that if the AI method hasn't been previously qualified for the specific context of use, the full model architecture, development logs, validation and testing records, training data, and data processing pipeline description would likely be considered parts of the clinical trial data or protocol dossier. These may be requested during marketing authorization assessment.
For practical purposes, this means:
- AI systems used for patient selection or stratification must be documented in the protocol
- AI-driven endpoint analysis should follow pre-specified statistical analysis plans
- If you're using an AI medical device to generate clinical evidence (imaging endpoints, digital biomarkers), the device must be adequate for evidence generation even if it carries a CE mark — CE marking alone is insufficient
- The regulatory risk increases as you move from early-stage to pivotal clinical trials
Precision medicine
The EMA designates AI/ML used for indication or dosology decisions as both high patient risk and high regulatory impact. This is the highest-scrutiny category. If your AI system individualizes treatment based on patient characteristics, you must:
- Subject the system to special care in validation and documentation
- Provide guidance for prescribers on how the AI-driven recommendations work
- Include fall-back treatment strategies for technical failures
- Document how the system handles edge cases and outlier patient populations
Product information
AI used to draft, compile, edit, or translate product information (SmPC, package leaflets) must go through quality review mechanisms. The AI-generated text is not the concern — the accuracy and regulatory compliance of the output is. This means human review of AI-generated product information is non-negotiable.
Manufacturing
AI/ML used in drug manufacturing must follow ICH quality risk management principles (ICH Q9, Q10). The EMA anticipates AI use in manufacturing will increase and expects compliance with existing GMP frameworks. Process analytical technology (PAT) applications using AI for real-time release testing are a natural use case, but the AI models must be validated within the quality management system.
Post-authorization
This stage covers pharmacovigilance, post-authorization safety studies, and effectiveness studies. The EMA is clear: the marketing authorization holder must validate, monitor, and document model performance, and include AI/ML operations within the pharmacovigilance system.
If AI is used for adverse event classification and severity scoring, the MAH is responsible for monitoring model performance. If a post-authorization study is a condition of the marketing authorization, the AI/ML applications used must be agreed with regulators during authorization assessment — not introduced unilaterally afterward.
Key principles across all stages
Risk-based approach
The EMA mirrors the EU AI Act's risk-based philosophy but applies it specifically to the drug lifecycle. The principle is proportionality: the higher the patient risk or regulatory impact, the more rigorous the development, validation, documentation, and monitoring requirements.
Transparency and explainability
This is where the EMA shows pragmatism. The paper acknowledges that "black box" models — where the internal decision logic cannot be fully explained — are sometimes unavoidable. In such cases, the EMA accepts "interpretability" as an alternative: you must demonstrate human oversight and transparency over questions arising when the model doesn't perform as expected or isn't sufficiently robust. Discuss this with the EMA through qualification or scientific advice procedures.
Data integrity
Training data must be free from bias. If you're using a third-party AI system in a high regulatory impact or high patient risk context, the software developer must provide sufficient details through a methodology qualification process covering the specific context of use. Your SOPs implementing GxP principles on data and algorithm governance must extend to cover all data and models used for high-impact AI applications.
Regulatory interaction
The EMA recommends early engagement for any AI application where no clearly applicable written guidance exists. Two pathways are available: the Innovation Task Force (ITF) for early-stage experimental technology, and formal scientific advice or qualification of innovative development methods for more mature applications.
How this compares to the FDA approach
The FDA and EMA share the same objective — safe and effective AI implementation — but their regulatory philosophies diverge in ways that matter for global clinical programs.
The FDA is dialogue-driven. The FDA's approach, articulated through its January 2025 draft guidance on AI in drug and biological product development, emphasizes flexible, context-specific assessment through direct engagement with industry. This creates case-by-case precedent but can produce uncertainty about general expectations.
The EMA is structure-driven. The reflection paper establishes explicit requirements mapped to each lifecycle stage, with clear risk categories and defined compliance pathways. This provides more predictable paths to market but may slow early-stage AI adoption where the framework feels prescriptive.
Where they converge: In March 2026, the FDA and EMA jointly published ten guiding principles for AI in the medicines lifecycle, signaling a push toward regulatory harmonization. The principles emphasize a human-centric, risk-based approach with proportional validation, data governance, lifecycle performance monitoring, and multidisciplinary expertise.
For global clinical programs, the practical implication is: build your AI documentation to the EMA's more structured requirements, and you'll meet the FDA's expectations too. The reverse is not always true.
Compliance callout
If your trial spans US and EU sites, structure your AI documentation to the EMA standard. Include the full model architecture, training data provenance, validation records, and pre-specified analysis plans in the protocol dossier. This satisfies both the EMA's explicit requirements and the FDA's credibility framework. See our FDA 7-Step AI Credibility Framework guide for the US-side requirements.
What to do now
Audit your AI touchpoints. Map every AI/ML system used across your drug development program. For each, determine whether it falls into the EMA's "high patient risk" or "high regulatory impact" categories. If either applies, flag it for enhanced documentation and early regulatory engagement.
Update your SOPs. Your GLP, GCP, and GMP standard operating procedures must explicitly address AI/ML use. This isn't optional — the EMA states that existing regulatory principles "directly apply" to AI/ML, and your quality systems must reflect this.
Document proactively. For any AI system used in a clinical trial context, maintain comprehensive records of model architecture, training data, validation methodology, and performance monitoring. Treat this documentation as part of the trial dossier from day one — not as an afterthought during the marketing authorization application.
Engage early. If your AI application is novel and no applicable guidance exists, use the EMA's Innovation Task Force or scientific advice pathways. The EMA has explicitly encouraged early regulatory interaction for high-impact AI use cases.
Plan for the EU AI Act overlap. The EU AI Act's high-risk obligations for medical device AI take effect August 2026, with full compliance required by August 2027. The EMA reflection paper is designed to align with these requirements, but the operational burden of dual compliance (medicinal product regulation plus AI Act) should be factored into your regulatory strategy now.
Source: European Medicines Agency. "Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle." EMA/CHMP/CVMP/83833/2023. Adopted September 2024.
This is Guide #02 in the ClinStacks AI Compliance series. See also: Guide #01 — FDA 7-Step AI Credibility Framework.
The EMA's documentation requirements assume that training data and validation evidence exist. Our analysis of 1,000+ open medical imaging datasets reveals how uneven that evidence base actually is — and why AI endpoints may be the weakest link in modern trial design.